TOKYO – Japan's Anges MG Inc. said a new inflammation treatment it has been developing since 1999 should reach the Japanese market as early as next year.
TOKYO – Japanese biopharmaceutical companies are bracing for tough years ahead, as cuts in the costs of medicine at home and issues of getting new drugs to the market begin to bite. For some, the response is to step up development of new drugs.
TOKYO – Japan’s Nitto Denko Corp., which produces everything from electronics to chemicals, will spin off a small biopharmaceutical unit on April 1. Kageshi Maruyama, who will become president of the new company, told BioWorld Asia the decision was made to establish Nitto Biopharma Inc. to allow the company to operate in the market with more flexibility.
TOKYO – Japanese biopharmaceutical companies are bracing for tough years ahead, as cuts in the costs of medicine at home and issues of getting new drugs to the market begin to bite. For some, the response is to step up development of new drugs.
TOKYO – Japan's Nitto Denko Corp., which produces everything from electronics to chemicals, will spin off a small biopharmaceutical unit on April 1. Kageshi Maruyama, who will become president of the new company, told BioWorld Today that the decision was made to establish Nitto Biopharma Inc. to allow the company to operate in the market with more flexibility.
TOKYO – Japan will lower the prices of 45 drugs in the second quarter as part of a push to reduce spending in health care and encourage the use of generics. Among the drugs most likely to be affected by the move are Gilead Sciences Inc.'s popular hepatitis C virus (HCV) drugs Sovaldi and Harvoni.
TOKYO – Japan will lower the prices of 45 drugs in the second quarter as part of a push to reduce spending in health care and encourage the use of generics. Among the drugs most likely to be affected by the move are Gilead Sciences Inc.’s popular hepatitis C virus (HCV) drugs Sovaldi and Harvoni.
